Fraunhofer Institute for Cell Therapy and Immunology IZI
Fraunhofer Institute for Cell Therapy and Immunology IZI

Department of Cell and Gene Therapy Development

Publications

  • Ammar D, Schapitz I, Luu M, Hudecek M, Meyer M, Taps T, Schröder B, Ivics Z, Sanges C, Franz P, Koehl U, Negre H, Johanna I, Awigena-Cook J. Accelerating development of engineered T cell therapies in the EU: current regulatory framework for studying multiple product versions and T2EVOLVE recommendations. Front Immunol. 2023, Nov, 14: 1280826. doi: 10.3389/fimmu.2023.1280826
  • Auw N von, Serfling R, Kitte R, Hilger N, Zhang C, Gebhardt C, Dünkel A, Franz P, Köhl U, Fricke S, Tretbar SU. Comparison of two lab-scale protocols for enhanced mRNA-based CAR-T cell generation and functionality. Sci Rep 2023, 13 (1), article 18160. doi: 10.1038/s41598-023-45197-x
  • Blache U, Tretbar S, Koehl U, Mougiakakos D, Fricke S. CAR T cells for treating autoimmune diseases. RMD open 2023, 9 (4): e002907. doi: 10.1136/rmdopen-2022-002907
  • Blaudszun A-R, Kim W J, Um W, Yoon H Y, Shim M K, Kim K. Adoptive transfer of photosensitizer-loaded cytotoxic T cells for combinational photodynamic therapy and cancer immuno-therapy. Pharmaceutics. 2023,15 (4): 1295. doi: 10.3390/pharmaceutics15041295
  • Ciulean I S, Fischer J, Quaiser A, Bach C, Abken H, Tretbar U S, Fricke S, Köhl U, Schmiedel D, Grunwald T. CD44v6 specific CAR-NK cells for targeted immunotherapy of head and neck squamous cell carcinoma. Front Immunol 2023, 14: 1290488. doi: 10.3389/fimmu.2023.1290488
  • Feigl F F, Stahringer A, Peindl M, Dandekar G, Köhl U, Fricke S, Schmiedel D. Efficient redirection of NK cells by genetic modification with chemokine receptors CCR4 and CCR2B. Int J Mol Sci 2023, 24 (4), article 3129. doi: 10.3390/ijms24043129
  • Glatte B, Wenk K, Grahnert A, Friedrich M, Merz M, Vucinic V, Fischer L, Reiche K, Alb M, Hudecek M, Franz P, Fricke S, Platzbecker U, Koehl U, Sack U, Boldt A, Hauschildt S, Weiss R. Teclistamab impairs detection of BCMA CAR-T cells. Blood Adv 2023, 7 (15): 3842-3845. doi: 10.1182/bloodadvances.2023009714
  • Kitte R, Rabel M, Geczy R, Park S, Fricke S, Koehl U, Tretbar SU. Lipid nanoparticles outperform electroporation in mRNA-based CAR T cell engineering. Mol Ther Methods Clin Dev, 2023, 31: 101139. doi: 10.1016/j.omtm.2023.101139
  • Messer E K, Meyer A L, Klaeske K, Sieg F, Eifert S, Schmiedel D, Haunschild J, Jawad K, Saeed D, Hildebrandt L, Borger M A, Dieterlen M-T. The impact of obesity on T and NK cells after LVAD implantation. Obes Facts 2023, 16 (4): 364-373. doi: 10.1159/000530174
  • Rauch-Wirth L, Renner A, Kaygisiz K, Zimmermann L, Rodríguez Alfonso AA, Schütz D, Wiese S, Ständker L, Weil T, Schmiedel D,  Münch J. Optimized peptide nanofibrils as efficient transduction enhancers for in vitro and ex vivo gene transfer. Front Immunol. 2023, 14:1270243. doi: 10.3389/fimmu.2023.1270243
  • Bathini P, Sun T, Schenk M, Schilling S, McDannold N J, Lemere C A. Acute effects of focused ultrasound-induced blood-brain barrier opening on anti-pyroglu3 abeta antibody delivery and immune responses. Biomolecules. 2022 Jul 6;12(7):951. doi: 10.3390/biom12070951 
  • Bäumer N, Scheller A, Wittmann L, Faust A, Apel M, Nimmagadda SC, Geyer C, Grunert K, Kellmann N, Peipp M, Kailayangiri S, Ezequiel Gutierrez Suburu ME, Strassert CA, Schenk M, Greune L, Rüter C, Dersch P, Hartmann W, Rossig C, Neri D, Müller-Tidow C, Schwöppe C, Schliemann C, Khandanpour C, Lenz G, Berdel WE, Bäumer S. Electrostatic anti-CD33-antibody-protamine nanocarriers as platform for a targeted treatment of acute myeloid leukemia. J Hematol Oncol. 2022 Dec 1;15(1):171. doi: 10.1186/s13045-022-01390-5 
  • Beckmann L, Tretbar S, Kitte R, Tretbar M. Anticancer activity of natural and semi-synthetic drimane and coloratane sesquiterpenoids. Molecules 2022, 27 (8), article 2501. doi: 10.3390/molecules27082501
  • Blache U, Ford EM, Ha B, Rijns L, Chaudhuri O, Dankers PYW, Kloxin AM, Snedeker JG, Gentleman E. Engineered hydrogels for mechanobiology. Nat Rev Methods Primers 2, 98 (2022). doi: 10.1038/s43586-022-00179-7
  • Blache U, Popp G, Dünkel A, Köhl U, Fricke S. Potential solutions for manufacture of CAR T cells in cancer immunotherapy. Nat Commun 13, 5225 (2022). doi: 10.1038/s41467-022-32866-0
  • Heggli I, Blache U, Herger N, Mengis T, Jaeger PK, Schupbach R, Farshad-Amacker N, Brunner F, Snedeker JG, Farshad M, Distler O, Dudlis S. FGF2 overrides key pro-fibrotic features of bone marrow stromal cells isolated from Modic type 1 change patients. Eur Cell Mater. 2022 Oct 18;44:101-114. doi: 10.22203/eCM.v044a07 
  • Jasinski-Bergner S, Bluemke J, Bauer M, Skiebe S L, Mandelboim O, Wickenhauser C, Seliger B. Novel approach to identify putative Epstein–Barr–virus microRNAs regulating host cell genes with relevance in tumor biology and immunology. Oncoimmunology. 2022 May 1;11(1):2070338. doi: 10.1080/2162402X.2022.2070338. eCollection 2022 
  • Jasinski-Bergner S, Eckstein M, Taubert H, Wach S, Fiebig C, Strick R, Hartmann A, Seliger B. The human leukocyte antigen G as an immune escape mechanism and novel therapeutic target in urological tumors. Front Immunol. 2022 Feb 3;13:811200. doi: 10.3389/fimmu.2022.811200. eCollection 2022 
  • Jasinski-Bergner S, Schmiedel D, Mandelboim O, Seliger B. Role of HLA-G in viral infections. Front Immunol. 2022 Feb 14;13:826074. doi: 10.3389/fimmu.2022.826074. eCollection 2022 
  • Ruppel K, Fricke S, Köhl U, Schmiedel D. Taking lessons from CAR-T Cells  and going beyond: tailoring design and signaling for CAR-NK cells in cancer therapy. Front Immunol 2022, 13, article 822298. doi: 10.3389/fimmu.2022.822298
  • Schaffert A, Karkossa I, Ueberham E, Schlichting R, Walter K, Arnold J, Blüher M, Heiker J T, Lehmann J, Wabitsch M, Escher B I, Bergen M, Schubert K. Di-(2-ethylhexyl) phthalate substitutes accelerate human adipogenesis through PPARγ activation and cause oxidative stress and impaired metabolic homeostasis in mature adipocytes. Environ Int. 2022 Jun;164:107279. doi: 10.1016/j.envint.2022.107279. Epub 2022 May 6 
  • Strobelt R, Adler J, Paran P, Yahalom-Ronen Y, Melamed S, Politi B, Shulman Z, Schmiedel D, Shaul Y. Imatinib inhibits SARSCoV-2 infection by an offtarget-mechanism. Sci Rep 2022, 12, article 5758. doi: 10.1038/s41598-022-09664-1
  • Blache U, Weiss R, Boldt A, Kapinsky M, Blaudszun AR, Quaiser A, Pohl A, Miloud T, Burgaud M, Vucinic V, Platzbecker U, Sack U, Fricke S, Koehl U. Advanced flow cytometry assays for immune monitoring of CAR-T cell applications. Front Immunol. (2021), 12, 658314. doi: 10.3389/fimmu.2021.658314
  • Hansen M, Stahl L, Heider A, Hilger N, Sack U, Kirschner A, Cross M, Fricke S. Reduction of graft-versus-host-disease in NOD.Cg-Prkdcscid Il2rgtm1Wjl/SzJ (NSG) mice by cotransplantation of syngeneic human umbilical cord-derived mesenchymal stromal cells. Transplant Cell Ther. 27 (2021), 8, 658, e1-658.e10. doi: 10.1016/j.jtct.2021.04.018
  • Hartlage-Rübsamen M, Bluhm A, Moceri S, Machner L, Köppen J, Schenk M, Hilbrich I, Holzer M, Weidenfeller M, Richter F, Coras R, Serrano G E , Beach T G , Schilling S, von Hörsten S, Xiang W, Schulze A, Roßner S. A glutaminyl cyclase-catalyzed α-synuclein modification identified in human synucleinopathies. Acta neuropathologica (2021), 142 (3), S. 399–421. doi: 10.1007/s00401-021-02349-5
  • Häusner S, Herbst L, Bittorf P, Schwarz T, Henze C, Mauermann M, Ochs J, Schmitt R, Blache U, Wixmerten A, Miot S, Martin I, Pullig O. From single batch to mass-production-automated platform design concept for a phase II clinical trial tissue engineered cartilage product. Front Med (Lausanne). (2021), 8, 712917. doi: 10.3389/fmed.2021.712917
  • Hoffmann T, Rahfeld J-U, Schenk M, Ponath F, Makioka K, Hutter-Paier B, Lues I, Lemere C, Schilling S. Combination of the glutaminyl cyclase inhibitor PQ912 (Varoglutamstat) and the murine monoclonal antibody PBD-C06 (m6) shows additive effects on brain Aβ pathology in transgenic mice. Int J Mol Sci. 22 (2021), 21, 11791. doi: 10.3390/ijms222111791
  • Kitte R, Tretbar M, Dluczek S, Beckmann L, Marquardt P, Duenkel A, Schubert A, Fricke S, Tretbar US. Chemical and cytotoxic activity of three main sesquiterpenoids from Warburgia ugandensis. Results in Chemistry (2021), 3, 100242. doi: 10.1016/j.rechem.2021.100242
  • Kürzel S, Blaudszun A-R, Stahl L, Herbst R, Krochinsky F, Birkmann J, Hänel A, Schäfer-Eckart K, Ehninger G, Fiedler F, Bornhäuser M , Fricke S, Hänel M. Dexa-BEAM versus MIFAP as salvage regimen for recurrent lymphoma: a prospective randomized multicenter phase II trial with a median follow-up of 14.4 years. J Cancer Res Clin Oncol. (2021), doi: 10.1007/s00432-021-03702-7
  • Lidzba N, Arteaga V G, Schiermeyer A, Havenith H, Muranyi I, Schillberg S, Lehmann J, Ueberham E. Development of monoclonal antibodies against pea globulins for multiplex assays targeting legume proteins. J Agric Food Chem. 69 (2021), 9, Seite 2864-2874. doi: 10.1021/acs.jafc.0c07177
  • Röder M, Wiacek C, Lankamp F, Kreyer J, Weber W, Ueberham E. Improved sensitivity of allergen detection by immunoaffinity LC-MS/MS using ovalbumin as a case study. Foods 10 (2021), 12, 2932. doi: 10.3390/foods10122932
  • Sack U, Fricke S. Can flow cytometry outperform genetic testing in eosinophilia patients? Cytometry A 99 (2021), 8 Seite 772-773. doi: 10.1002/cyto.a.24311
  • Schaffert A, Krieg L, Weiner J, Schlichting R, Ueberham E, Karkossa I, Bauer M, Landgraf K, Junge K M, Wabitsch M, Lehmann J, Escher B I, Zenclussen A C, Körner A, Blüher M, Heiker J T, Bergen M, Schubert K. Alternatives for the worse: molecular insights into adverse effects of bisphenol a and substitutes during human adipocyte differentiation. Environ Int. (2021), 156:106730. doi: 10.1016/j.envint.2021.106730
  • Schlegel K, Lidzba N, Ueberham E, Eisner P, Schweiggert-Weisz U. Fermentation of lupin protein hydrolysates - effects on their functional properties, sensory profile and the allergenic potential of the major lupin allergen lup an 1. Foods 10 (2021), 2, 281. doi: 10.3390/foods10020281
  • Schmiedel D, Hezroni H, Hamburg A, Shulman Z. Brg1 supports B cell proliferation and germinal center formation through enhancer activation. Front Immunol. (2021) 12, 705848. doi: 10.3389/fimmu.2021.705848
  • Shibru B, Fey K, Fricke S, Blaudszun A-R, Fürst F, Weise M, Seiffert S, Weyh MK, Köhl U, Sack U, Boldt A. Detection of immune checkpoint receptors - a current challenge in clinical flow cytometry. Front Immunol. (2021), 12, 694055. doi: 10.3389/fimmu.2021.694055
  • Stauber T, Wolleb M, Duss A, Jaeger P K, Heggli I, Hussein A A, Blache U, Snedeker J G. Extrinsic macrophages protect while tendon progenitors degrade: insights from a tissue engineered model of tendon compartmental crosstalk. Adv Healthc Mater. (2021), 10, 20, e2100741. doi: 10.1002/adhm.202100741
  • Sun T, Shi Q, Zhang Y, Power C, Hoesch C, Antonelli S, Schroeder MK, Caldarone BJ, Taudte N, Schenk M, Hettmann T, Schilling S, McDannold NJ, Lemere CA. Focused ultrasound with anti-pGlu3 Aβ enhances efficacy in Alzheimer's disease-like mice via recruitment of peripheral immune cells. J Control Release. (2021), 336, Seite 443-456. doi: 10.1016/j.jconrel.2021.06.037
  • Vucinic V, Quaiser A, Lückemeier P, Fricke S, Platzbecker U, Koehl U. Production and application of CAR T Cells: current and future role of europe. Front Med (Lausanne) (2021), 8, 713401. doi: 10.3389/fmed.2021.713401
  • Walcher L, Kistenmacher AK, Sommer C, Böhlen S, Ziemann C, Dehmel S, Braun A, Tretbar US, Klöß S, Schambach A, Morgan M, Löffler D, Kämpf C, Blumert C, Reiche K, Beckmann J, König U, Standfest B, Thoma M, Makert GR, Ulbert S, Kossatz-Böhlert U, Köhl U, Dünkel A, Fricke S. Low energy electron irradiationiIs a potent alternative to gamma irradiation for the inactivation of (CAR-)NK-92 cells in ATMP manufacturing. Front Immunol. (2021), 12, 684052. doi: 10.3389/fimmu.2021.684052
  • Fertey J, Thoma M, Beckmann J, Finkensieper J, Reißhauer S, Berneck BS, Issmail L, Schönfelder J, Casado JP, Poremba A, Rögner F-H, Standfest B, Makert GR, Walcher L, Kistenmacher A-K, Fricke S, Grunwald T, Ulbert S, Bayer L. Automated application of low energy electron irradiation enables inactivation of pathogen- and cell-containing liquids in biomedical research and production facilities. Scientific reports 10 (2020) 1, Artikel-Nr.: 12786, 14 Seiten. dx.doi.org/10.1038/s41598-020-69347-7
  • Walcher L, Hilger N, Wege AK, Lange F, Tretbar S, Blaudszun A-R, Fricke S. Humanized mouse model: hematopoietic stemcell transplantation and tracking using short tandem repeat technology. Immunity, inflammation and disease (2020) Seite 1-8. dx.doi.org/10.1002/iid3.317
  • Dluczek S, Tretbar US, Fricke S, Koehl U. CAR-T-Zellen: Update 2019. Transfusionsmedizin 9 (2019), 3, Seiten 187-200, dx.doi.org/10.1055/a-0833-2631
  • Kloess S, Kretschmer A, Stahl L, Fricke S, Koehl U. CAR-Expressing Natural Killer Cells for Cancer Retargeting. Transfus Med Hemother. 2019 Feb;46(1):4-13. dx.doi.org/10.1159/000495771
  • Stahl L, Duenkel A, Hilger N, Tretbar US, Fricke S. The epitope-specific anti-human CD4 antibody MAX.16H5 and its role in immune tolerance. Frontiers in immunology 10 (2019), article 1035, 12 Seiten, dx.doi.org/10.3389/fimmu.2019.01035
  • Walcher L, Müller C, Hilger N, Kretschmer A, Stahl L, Wigge S, Rengelshausen J, Müller AM, Fricke S. Effect of combined sublethal X-ray irradiation ancyclosporine a treatment in NOD scid gamma (NSG) mice. Experimental animals 68 (2019), 1, Seite 1-11, dx.doi.org/10.1538/expanim.18-0056